Boeing : Is taking flight
Entry price | Target | Stop-loss | Potential |
---|
$73.97 |
$0 |
$73.4 |
-100% |
---|
The american multinational aerospace company announced on Friday 22th, a cooperation with Airbus and Embraer for commercialization of biofuels for aviation. Companies signed a memorandum of understanding to collaborate on biofuels development at reasonable cost.
The weight of the penalties which the aircraft manufacturer will have to pay for 2012 may impact net income. Consequently, EPS is revised downward at 4.5 USD. From fundamental viewpoint, Boieng is a strong and promising company. Turnover growth significantly with expectations at 79 billion dollars for 2012 and order book is full. Consensus is unanimous with 21 analysts at “Buy” and “Outperform” and 9 at “Hold” on 30 financials following the stock.
Technically Boeing is in consolidation phase in its 72/76 USD range. The 50 and 20-days moving averages seem marked a deceleration but moving average 100-days will probably come in support. Moving average 20 weeks show an upward trend which may support the trend during the next few weeks.
Investors may entertain the current level to take a buying position on the stock with an objective at 79 USD, and probably higher on the way to the highest historical. A stop loss will be engaged at 73.4 USD.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.